LABQUALITY

THE PATH TO PERFECT QUALITY

EXTERNAL QUALITY ASSESSMENT 2023

MICROBIOLOGY

WWW.LABQUALITY.COM | INFO@LABQUALITY.FI

Service information

Labquality – EQAS

Labquality is an independent Finnish external quality assessment provider. Labquality has more than 50 years of experience in helping clinical laboratories and POCT sites develop and maintain their performance. Labquality's EQA schemes are internationally recognized high quality programs. The EQA programs have a clinical scope with an educational touch. Part of the EQA production is outsourced to expert laboratories and national partners.

Integrated EQA service (EQA³)

Labquality is the first EQA provider that has integrated pre-analytical, analytical and post-analytical phases to its EQA programs. Advanced and traditional EQA schemes have been designed to fully support the total quality management system of the participating laboratories and fulfill ISO 15189 requirements concerning the extra-analytical phases. In addition to the samples, the integrated schemes include pre- and/or post-analytical questionnaires concerning the scope of the scheme.

Quality management

Labquality's management system is certified according to ISO 9001 (DQS) and the main EQA schemes are accredited according to ISO 17043 (PT02/FINAS). The scope of accreditation is available on the FINAS website: **www.finas.fi**, and the accreditation status of the EQA schemes is available on our website: **www.labquality.fi/en**. The list of accredited schemes will be provided upon request.

EQA service availability

Labquality has customers in over 50 countries in Europe, Asia, America and North Africa. Service is localized by 40 national partners. All digital schemes, including pre-analytical schemes and diagnostic schemes for anatomic pathology, are available globally. With only a few exceptions all schemes are globally available through national partner. For direct customers, the program selection is limited to the schemes with stabile and non-hazardous sample materials.

Enrolment and prices

Labquality has annual programs and pricing. Participants shall place their orders for the following year before the end of November to ensure their participation in all needed EQA rounds. Enrolment is possible during the calendar year, but only part of the EQA rounds may be available. To place an order, please contact our national partner in your country or Labquality's customer service at info@labquality.com

Distributions

Labquality's specimen logistics system is accepted and continuously audited as part of accreditation according to the ISO 17043 (PT02/FINAS) standard. Specimens are shipped according to the annual schedule. Labquality retains the right to make changes in the schedule.

LabScala EQA portal

Partners and participants are able to handle the whole EQA process from orders to reports through a modern web based software, LabScala. The EQA process is designed to go along with the laboratory process from pre-analytics to post-analytics. Easy availability and user-friendly interface guarantee an advanced experience.

Certificate

A certificate of participation will be provided upon request at the end of the calendar year. The certificate refers to EQA reports to evaluate the performance of the participant.

Customer service

Please contact Labquality's international partners (listed on our website: www.labquality.com) or our customer service: info@labquality.fi

How to use the catalogue



Results processed: The number shows how many results from different analyzers or tests within the same laboratory are allowed depending on scheme, when the sample volume is sufficient. Schemes marked with * allow multiple results reporting only, if they are analyzed with different methods.

Microbiology

The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in the areas of bacterial serology, bacteriology, mycology, parasitology and virology. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, and PCR tests, solutions for versatile needs are available. Authentic single donor samples are included in multiple schemes.

Microbiology » **Bacterial Serology**

5840 Antistreptolysin

3*

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 2 liquid human serum or plasma samples, 0.4 mL
Authentic, commutable, single donor samples.

Examinations: Qualitative and quantitative ASO

5950 *Bordetella pertussis*, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●				●			●	

EQA³

Specimens: 2 liquid human serum samples, 0.3 mL

Examinations: *B. pertussis* IgA, IgG & IgM antibodies, Pertussis toxin IgA, IgG & IgM, post-analytical clinical interpretation

5960 *Borrelia burgdorferi*, antibodies, European origin

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●				●			●	

EQA³

Specimens: 2 liquid human serum or plasma samples, 0.5 mL
Authentic, commutable, single donor samples.

Examinations: *B. burgdorferi* IgG, IgM and total antibodies, post-analytical clinical interpretation

5965 CXCL 13 Chemokine

3

1	2	3	4	5	6	7	8	9	10	11	12
●					●						

NEW

Specimens: 2 liquid samples

Examinations: Chemokine CXCL13 detection

5620 *Chlamydia pneumoniae*, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

EQA³

Specimens: 3 liquid serum or plasma samples, 0.4 mL

Examinations: *C. pneumoniae* IgA, IgG, IgM antibodies, post-analytical clinical interpretation

5851 *Francisella tularensis*, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
			●						●		

Specimens: 3 liquid human serum or plasma samples, 0.5 mL

Examinations: *Francisella tularensis* IgG, IgM and total antibodies

5860 *Helicobacter pylori*, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

EQA³ POCT

Specimens: 2 liquid human serum or plasma samples, 0.4 mL

Examinations: *H. pylori* IgA, IgG and total antibodies, quantitative and qualitative tests, post-analytical clinical interpretation

Notes: For clinical laboratories and POCT sites

5980 *Mycoplasma pneumoniae*, antibodies

3*

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●		●	

EQA³ POCT

Specimens: 2 liquid human serum or plasma samples, 0.3 mL
Authentic, commutable, single donor samples.

Examinations: *M. pneumoniae* IgG, IgM and total antibodies, post-analytical clinical interpretation

Notes: For clinical laboratories and POCT sites

5880 Syphilis serology

3*

1	2	3	4	5	6	7	8	9	10	11	12
	●				●				●		●

EQA³

Specimens: 2 liquid human serum samples, 0.6 mL
Authentic, commutable, single donor samples.

Examinations: Cardiolipin, *Treponema pallidum* antibodies, post-analytical clinical interpretation

5050 Bacteriological staining, direct (digital images)

1	2	3	4	5	6	7	8	9	10	11	12
			●						●		

3

Specimens: 3 cases, 3–9 digital images

Examinations: Interpretation of digital images taken from direct bacteriological Gram staining of clinical samples

5100 Blood culture

1	2	3	4	5	6	7	8	9	10	11	12
		●		●					●		●

1

Specimens: 2 lyophilized samples. Brief case histories are also given. Fresh blood is needed for specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.

Examinations: Culture, identification, antimicrobial susceptibility

Notes: Fresh blood is needed but not included in the shipment

5101 Blood culture, screening

1	2	3	4	5	6	7	8	9	10	11	12
		●		●					●		●

1

Specimens: 2 lyophilized samples. Brief case histories are also given. Fresh blood is needed for sample preparation.

Examinations: Culture, preliminary identification using Gram staining. The scheme is also suitable for stem cell banks screening only for possible growth. **Notes:** Fresh blood is needed but not included in the shipment

5150 Cerebrospinal fluid, bacterial culture

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●			●

1

Specimens: 2 lyophilized samples. Brief case histories are also given.

Examinations: Culture and identification. The scheme is also suitable for laboratories performing screening and reporting merely a preliminary identification.

Notes: See also scheme 5303 Meningitis-encephalitis multiplex, nucleic acid detection

5612 *Chlamydia trachomatis* and *Neisseria gonorrhoeae* nucleic acid detection

1	2	3	4	5	6	7	8	9	10	11	12
		●		●			●			●	

3

Specimens: 3 simulated swab/urine samples, 2 mL
Examinations: Detection of *C. trachomatis* and *N. gonorrhoeae* nucleic acid

Notes: See also scheme 5302 Sexually transmitted diseases multiplex, nucleic acid detection

5200 *Clostridioides difficile*, culture and toxin detection

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

1

Specimens: 2 lyophilized mixtures of bacteria

Examinations: This scheme includes *C. difficile* culture, antigen detection (GDH), toxin detection and direct nucleic acid detection. Hypervirulent *C. difficile* strains also included.

5202 *Clostridioides difficile*, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 2 lyophilized mixtures of bacteria

Notes: Only in connection with scheme 5200

5201 *Clostridioides difficile*, nucleic acid detection

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

1

Specimens: 2 lyophilized mixtures of bacteria

Examinations: *C. difficile* direct nucleic acid detection. Hypervirulent *C. difficile* strains also included.
Notes: 5200 includes also this examination

5191 Faecal bacterial pathogens multiplex, nucleic acid detection

1	2	3	4	5	6	7	8	9	10	11	12
			●		●				●		●

1

Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL.

Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, *E. coli* EHEC (stx1/stx2), *E. coli* EAEC, *E. coli* EIEC, *E. coli* EPEC, *E. coli* ETEC, Plesiomonas, Salmonella, Shigella and Yersinia.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5230 *Mycobacterium tuberculosis*, drug resistance

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

NEW

Specimens: 2 simulated samples, 1 mL

Examinations: *Mycobacterium tuberculosis* nucleic acid detection, rifampicin susceptibility and isoniazid susceptibility

5190 Faecal culture

1

1	2	3	4	5	6	7	8	9	10	11	12
			●		●				●		●

Specimens: 2 lyophilized mixtures of bacteria

Examinations: Culture and direct nucleic acid detection. Pathogens included are *Aeromonas, Campylobacter, Plesiomonas, Salmonella*, *Shigella* and *Yersinia*.

5080 General Bacteriology 1 (aerobes and anaerobes)

1

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●			●

EQA[3]

Specimens: 4 lyophilized mixtures of microbes: both pathogens and normal flora. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases

Notes: 5080 includes 5081, General Bacteriology 2

5081 General Bacteriology 2 (aerobes)

1

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●			●

EQA[3]

Specimens: 2 lyophilized mixtures of microbes: both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases

Notes: 5080 General Bacteriology 1 includes 5081

5041 Gram stain, blood culture

1

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

Specimens: 2 air-dried, unfixed microbe suspensions on slides. Brief case histories also given.

Examinations: Staining and microscopy

5040 Gram stain, colonies

1

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

Specimens: 3 air-dried, unfixed microbe suspensions on a slide

Examinations: Staining and microscopy

5596 *Helicobacter pylori*, antigen detection in faeces

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

POCT

Specimens: 3 samples: lyophilized faecal or swab
Examinations: Antigen detection

Notes: For clinical laboratories and POCT sites

5597 Legionella, antigen detection in urine

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●			●

POCT

Specimens: 3 simulated urine samples

Examinations: Legionella antigen detection

5220 Mycobacterial culture and stain

1

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

Specimens: 2 lyophilized samples and 2 fixed smears on slides

Examinations: Detection of *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis* complex and atypical mycobacteria: culture, direct nucleic acid detection, acid-fast staining and microscopy

Notes: See also product 5250 IGRA for *M. tuberculosis*

5221 Mycobacterial nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

Specimens: 2 lyophilized samples

Examinations: Direct nucleic acid detection

Notes: 5220 includes also this examination. For additional set of samples, order scheme 5222

5222 Mycobacteria, extra set of samples

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

Specimens: 2 lyophilized samples

Notes: Only in connection with scheme 5220 or 5221

5240 Mycobacterial stain

1

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

Specimens: 2 fixed smears on slides

Examinations: Acid-fast staining and microscopy

5120 *Neisseria gonorrhoeae* (Gc), culture and susceptibility testing

1

1	2	3	4	5	6	7	8	9	10	11	12
		●		●			●			●	

Specimens: 2 lyophilized mixtures of microbes. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.

Examinations: Culture, identification and antimicrobial susceptibility testing. Also suitable for laboratories performing preliminary screening.

5180 Salmonella culture

1

1	2	3	4	5	6	7	8	9	10	11	12
			●		●				●		●

Specimens: 2 lyophilized mixtures of bacteria **Examinations:** Culture

Notes: 5190 also includes 5180

POCT

5599 *Streptococcus agalactiae* (GBS), nucleic acid detection

3*

1	2	3	4	5	6	7	8	9	10	11	12
			●		●			●		●	

Specimens: 2 swab samples. Samples also include normal flora.
Examinations: Direct nucleic acid detection

Notes: See also product 5594 for *S. agalactiae* (GBS) culture.

5594 *Streptococcus agalactiae* (GBS), culture

1

1	2	3	4	5	6	7	8	9	10	11	12
			●		●			●		●	

Specimens: 2 lyophilized samples. Samples include pathogens and/or normal flora.

Examinations: Culture
Notes: See also product 5599 for direct nucleic acid detection.

POCT

5598 *Streptococcus pneumoniae*, antigen detection in urine

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●			●

Specimens: 3 simulated urine specimens

Examinations: *S. pneumoniae* antigen detection

POCT

5595 *Streptococcus pyogenes* (Group A), antigen detection in pharyngeal sample

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●			●

Specimens: 3 simulated pharyngeal samples
Examinations: Antigen detection

Notes: For clinical laboratories and POCT sites. Three results if used different kits.

5593 *Streptococcus pyogenes* (Group A), nucleic acid detection in pharyngeal sample

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●			●

Specimens: 3 simulated pharyngeal samples **Examinations:** Nucleic acid detection. **Notes:** Three results if used different kits.

5073 Surveillance for multidrug resistant bacteria, gramnegative rods

1

1	2	3	4	5	6	7	8	9	10	11	12
	●				●			●		●	

Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora

Examinations: The scheme is intended for laboratories performing screening of multidrug resistant gramnegative rods (e.g. CPE, ESBL, MDR *Acinetobacter* and *P. aeruginosa)* by culture and/or direct nucleic acid detection method

5071 Surveillance for multidrug resistant bacteria, MRSA

1

1	2	3	4	5	6	7	8	9	10	11	12
	●				●			●		●	

Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora

Examinations: The scheme is intended for laboratories performing screening of MRSA (methicillin resistant *Staphylococcus aureus*) by culture and/or direct nucleic acid detection method

5072 Surveillance for multidrug resistant bacteria, VRE

1	1	2	3	4	5	6	7	8	9	10	11	12
		●				●			●		●	

Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora

Examinations: The scheme is intended for laboratories performing screening of VRE (vancomycin-resistant enterococci) by culture and/or direct nucleic acid detection method

5140 Throat streptococcal culture

1	1	2	3	4	5	6	7	8	9	10	11	12
			●		●			●			●	

Specimens: 3 lyophilized mixtures of bacteria

Examinations: Culture and identification of group A, C and G streptococci

5060 Urine culture, quantitative screening

1	1	2	3	4	5	6	7	8	9	10	11	12
			●			●			●			●

Specimens: 2 lyophilized samples and dilutor. Brief case histories also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Culture and quantitation, pre-and/or post-analytical indicators

Notes: Scheme 3170 available for urine bacterial screening with automated analyzers.

EQA[3]

5065 Urine culture, quantitative screening, identification and susceptibility

1	1	2	3	4	5	6	7	8	9	10	11	12
			●			●			●			●

Specimens: 2 lyophilized samples and dilutor. Brief case histories also given. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Culture, quantitation, identification and antimicrobial susceptibility testing, pre-and/or post-analytical indicators

Notes: Scheme 3170 available for urine bacterial screening with automated analyzers.

EQA[3]

Microbiology » **Mycology**

5261 Fungal infections, nucleic acid detection

3	1	2	3	4	5	6	7	8	9	10	11	12
				●						●		

Specimens: 3-4 simulated samples. The samples may include yeasts, dermatophytes and moulds. **Examinations:** Nucleic acid detection according to laboratory's own test selection.

Notes: Test selection of the participating lab is taken into consideration in result processing.

NEW

5260 Fungal culture

1	1	2	3	4	5	6	7	8	9	10	11	12
			●		●				●		●	

Specimens: 3 lyophilized samples. Brief case histories also given. The samples include moulds, dermatophytes and yeasts.

Examinations: Culture and identification. Antimicrobial susceptibility testing of yeast strains.

Microbiology » **Parasitology**

5472 Faecal parasites multiplex, nucleic acid detection

1	1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●	

Specimens: 3 lyophilized samples

Examinations: Nucleic acid detection of *Cryptosporidium, Dientamoeba fragilis, Entamoeba histolytica* and *Giardia lamblia.*

5430 Malaria, antigen and nucleic acid detection

3*	1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●	

Specimens: 3 whole blood samples

Examinations: Antigen and nucleic acid detection. Target antigens: HRP2 and/or pLDH and/or aldolase.

Notes: For clinical laboratories and POCT sites

POCT

5462 Malaria screening, Giemsa stain

3	1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●	

Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.

Examinations: Preliminary screening of malaria plasmodia

5463 Malaria screening, MGG stain

3	1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●	

Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.

Examinations: Preliminary screening of malaria plasmodia

5460 Parasites in blood, Giemsa stain

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

3

Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites

VIRTUAL

5470 Parasites in blood, Giemsa stain, virtual microscopy

1	2	3	4	5	6	7	8	9	10	11	12
										●	

5

Specimens: 2 virtual whole slide images of Giemsa stained smears prepared by using a scanner microscope. Brief case histories also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites

5461 Parasites in blood, MGG stain

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

3

Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites

VIRTUAL

5471 Parasites in blood, MGG stain, virtual microscopy

1	2	3	4	5	6	7	8	9	10	11	12
										●	

5

Specimens: 2 virtual whole slide images of MGG stained smears prepared by using a scanner microscope. Brief case histories also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites

5440 Parasites in faeces

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

1

Specimens: 3 stool samples in formalin. Brief case histories also given.

Examinations: Screening and identification of intestinal parasites (ova and parasites)

VIRTUAL

5450 Parasites in faeces, virtual microscopy

1	2	3	4	5	6	7	8	9	10	11	12
			●						●		

5

Specimens: Virtual whole slide images of stool samples in formalin prepared by using a scanner microscope. Brief case histories also given.

Examinations: Screening and identification of intestinal parasites (ova and parasites)

EQA[3]

5420 Toxoplasma, antibodies

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

3

Specimens: 3 liquid human plasma samples, 0.7 mL each. Brief case histories also given. Authentic commutable samples: Each sample batch originates from a single human donor.

Examinations: Toxoplasma IgA, IgG, IgM and total antibodies, IgG avidity, post-analytical clinical interpretation

POCT

5473 *Trichomonas vaginalis*, detection

1	2	3	4	5	6	7	8	9	10	11	12
	●		●				●		●		

3*

Specimens: 3 simulated samples

Examinations: Detection of *Trichomonas vaginalis* antigen and nucleic acid (NAT)

Microbiology » **Virology**

NEW

5556 HSV1&2/VZV/*T. pallidum*, nucleic acid detection

1	2	3	4	5	6	7	8	9	10	11	12
			●			●					

1

Specimens: 2-3 samples simulating swab samples taken from lesions

Examinations: Nucleic acid detection of HSV1, HSV2, VZV, *Treponema pallidum*

5651 CMV and EBV, nucleic acid detection, quantitative

1	2	3	4	5	6	7	8	9	10	11	12
		●						●			

3

Specimens: 5 samples simulating plasma, 1.5 mL
Examinations: CMV and EBV NAT (quantitative).

Notes: Quantitative result processing

EQA[3]

5650 Cytomegalovirus, antibodies

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●			●

3

Specimens: 3 liquid human plasma samples, 0.7 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Cytomegalovirus IgG, IgM and total antibodies, IgG avidity and post-analytical clinical interpretation

5635 Dengue virus, antibodies and antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●		●	

POCT

EQA³

Specimens: 3 human serum or plasma samples, 0.5 mL. Authentic, commutable samples from a single human donor or occasionally simulated samples.

Examinations: Dengue virus IgG and IgM antibodies, Dengue virus antigen (NS1) and post-analytical clinical interpretation

5640 EBV mononucleosis, POCT

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●			●

POCT

Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: MonAb
Notes: For clinical laboratories and POCT sites

5641 EBV mononucleosis, specific antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●			●

EQA³

Specimens: 3 liquid human plasma samples, 1.4 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: EBNA AbG, EBV VCA AbG, EBV VCA AbM, IgG Avidity and post-analytical clinical interpretation

5092 Hepatitis A, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

EQA³

Specimens: 3 liquid human plasma samples, 0.6 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: HAVAb, HAVAbM, HAVAbG and post-analytical clinical interpretation

5094–5096 Hepatitis B and C, serology, specimen volume 0.6 mL / 1.2 mL / 2.0 mL

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

EQA³

Specimens: 3 liquid human plasma samples, 0.6 / 1.2 or 2.0 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: HBcAb, HBcAbM, HBeAb, HBeAg, HBsAb (qual), HBsAg, HCVAb, HCVAbCt and post-analytical clinical interpretation

Volume specific product codes:
5094: for 0.6 mL human plasma specimens
5095: for 1.2 mL human plasma specimens
5096: for 2.0 mL human plasma specimens

5093 Hepatitis B, s-antigen antibodies, quantitative

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

Specimens: 2 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: HBsAb (anti-HBs), quantitative

5679 Hepatitis B virus, nucleic acid detection (DNA)

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●		●	

Specimens: 3 lyophilized or liquid plasma samples, 1.2 mL

Examinations: HBV DNA, quantitative and/or qualitative nucleic acid detection

5678 Hepatitis C virus, nucleic acid detection (RNA)

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●		●	

Specimens: 3 lyophilized or liquid plasma samples, 1.2 mL

Examinations: HCV RNA, quantitative and/or qualitative nucleic acid detection

5682 Hepatitis E, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
				●						●	

EQA³

Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Hepatitis E virus IgG and IgM antibodies, post-analytical clinical interpretation.

5555 Herpes simplex 1 and 2, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Occasionally simulated samples.

Examinations: HSV IgG (qualitative/quantitative), HSV IgM, HSV-1 IgG, HSV-2 IgG

5680 HIV-1, nucleic acid detection (RNA)

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●		●				●		●	

Specimens: 3 lyophilized or liquid plasma samples, 1.2 mL

Examinations: HIV-1 RNA, quantitative and/or qualitative nucleic acid detection

EQA³

5091 HIV, antibodies and antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 3 liquid human plasma 0.7 mL

Examinations: HIVAgAb (combo), HIVAb, HIVAg, HIVAbCt: primary and confirmatory tests, post-analytical clinical interpretation. Positive specimens may include HIV-1 or HIV-2.

POCT

5090 HIV, antibodies and antigen detection, POCT

3*

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 3 liquid human plasma 0.5 mL
Examinations: HIVAb and HIVAgAb primary tests (POCT)

Notes: Scheme 5091 is for clinical laboratories

5086 Human papillomavirus, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

Specimens: 2 simulated samples, 1 mL
Examinations: High-risk human papillomavirus NAT, hrHPVNAT

Notes: Suitable for nucleic acid methods used in cervical cancer screening

EQA³

5089 Human T-cell lymphotropic virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: HTLVAb: primary and confirmatory tests, post-analytical clinical interpretation. Positive samples may include HTLV-1 or HTLV-2.

5670 Influenza virus A+B and RS virus, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
	●									●	

Specimens: 5 artificial samples. 1 mL
Examinations: InfANAT, InfBNAT, RSVNAT

Notes: See also scheme 5300 Respiratory infections multiplex, nucleic acid detection

POCT

5671 Influenza virus A+B, antigen detection

3*

1	2	3	4	5	6	7	8	9	10	11	12
	●									●	

Specimens: 3 liquid and/or swab samples.
Examinations: InfAAg, InfBAg

Notes: For clinical laboratories and POCT sites. The samples are not suitable for IFA or NAT methods, please see scheme 5670 or 5562.

EQA³

5668 Measles virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Measles virus IgG and IgM antibodies and post-analytical clinical interpretation

5562 Multiple respiratory virus, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
	●					●				●	

Specimens: The round contains 3 swab samples.
Examinations: Influenza A/B virus NAT, RSV NAT and SARS-CoV-2 NAT

Notes: Scheme is not suitable for TMA methods (e.g. Hologic Panther SARS-CoV-2 assay).

EQA³

5669 Mumps virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Mumps virus IgG and IgM antibodies and post-analytical clinical interpretation

5675 Norovirus, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

Specimens: 3 simulated samples, 1 mL

Examinations: Norovirus NAT, genogroups GI and GII

5660 Parvovirus B19, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

EQA³

Specimens: 3 liquid human plasma or serum samples, 0.4 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Parvovirus IgG, IgM, IgG avidity and post-analytical clinical interpretation

5560 Puumala virus, antibodies

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●		●	

POCT

EQA³

Specimens: 3 liquid human plasma or serum samples, 0.3 mL. Brief case histories are also provided.

Examinations: Puumala virus IgG, IgM, POC tests and specific antibodies, IgG avidity and post-analytical clinical interpretation

Notes: For clinical laboratories and POCT sites

5673 Respiratory adenovirus, antigen detection

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

POCT

Specimens: 3 simulated samples, 1 mL

Examinations: Adenovirus Ag

5098 Rotavirus and adenovirus, antigen detection

3*

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

POCT

Specimens: 3 simulated samples, 1 mL

Examinations: Rotavirus and adenovirus antigen detection

5672 RS virus, antigen detection

3*

1	2	3	4	5	6	7	8	9	10	11	12
	●									●	

POCT

Specimens: 3 liquid and/or swab samples.
Examinations: RSVAg

Notes: For clinical laboratories and POCT sites. The samples are not suitable for IFA or NAT methods, please see scheme 5670 or 5562.

5667 Rubella virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

EQA³

Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Rubella virus IgG and IgM antibodies, IgG avidity and post-analytical clinical interpretation

5099 Tick-borne encephalitis virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
		●			●			●			●

EQA³

POCT

Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: TBE IgG, IgM, total antibodies and post-analytical clinical interpretation

Notes: For clinical laboratories and POCT sites

5677 SARS-CoV-2, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

POCT

Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: SARS-CoV-2 Ab, SARS-CoV-2 IgG, SARS-CoV-2 IgM, SARS-CoV-2 IgA

Notes: For clinical laboratories and POCT sites

5681 SARS-CoV-2, antigen detection

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

POCT

Specimens: 3 simulated samples
Examinations: SARS-CoV-2 Ag

Notes: For clinical laboratories and POCT sites

5676 SARS-CoV-2, nucleic acid detection

3

1	2	3	4	5	6	7	8	9	10	11	12
●			●			●			●		

POCT

Specimens: 3 simulated whole genome cDNA samples

Examinations: SARS-CoV-2 NAT

Notes: Including variants. Scheme is not suitable for TMA methods (e.g. Hologic Panther SARS-CoV-2 assay).

5665 Varicella-zoster virus, antibodies

EQA³ | 3

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 3 liquid human plasma or serum samples, 0.5 mL.
Authentic commutable samples: each batch originates from a single human donor.

Examinations: Varicella zoster IgG, IgM, total antibodies and post-analytical clinical interpretation

5636 Zika virus, antibodies

3

1	2	3	4	5	6	7	8	9	10	11	12
				●						●	

Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.

Examinations: Zika virus IgG, Zika virus IgM, clinical interpretation

EQA schemes suitable for direct nucleic acid testing methods » **Multiplex**

5191 Faecal bacterial pathogens multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
			●		●				●		●

Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL.

Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, *E. coli* EHEC (stx1/stx2), *E. coli* EAEC, *E. coli* EIEC, *E. coli* EPEC, *E. coli* ETEC, Plesiomonas, Salmonella, Shigella and Yersinia.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5472 Faecal parasites multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
	●			●			●			●	

Specimens: 3 lyophilized samples

Examinations: Nucleic acid detection of *Cryptosporidium*, *Dientamoeba fragilis*, *Entamoeba histolytica*, *Giardia lamblia*.

5304 Gastrointestinal viral multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
				●						●	

Specimens: 3 simulated samples, 1 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are: Adenovirus, Astrovirus, Norovirus, Rotavirus, Sapovirus.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5303 Meningitis-encephalitis multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●		●	

Specimens: 3 simulated samples, 1 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are: *Escherichia coli* K1, *Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae,* Cytomegalovirus (CMV), Enterovirus, Epstein-Barr virus (EBV), Herpes simplex virus 1 (HSV1), Herpes simplex virus 2 (HSV2), Human herpesvirus 6 (HHV6), Human parechovirus (HPeV), Varizella zoster virus (VZV) and *Cryptococcus neoformans/gattii.*

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5300 Respiratory infections multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
	●			●				●			●

Specimens: 4 simulated samples, 1 mL

Examinations: Direct multiplex nucleic acid detection. Pathogens included are adenovirus, *B. parapertussis, B. pertussis, C. pneumoniae,* coronavirus (OC43, 229E, NL63, HKU1), enterovirus, influenzavirus A/B, *L. pneumophila,* metapneumovirus, *M. pneumoniae,* parainfluenzavirus 1-4, rhinovirus, RSV A/B, SARS-CoV-2 and *S. pneumoniae*.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5302 Sexually transmitted diseases multiplex, nucleic acid detection

1

1	2	3	4	5	6	7	8	9	10	11	12
		●		●			●			●	

Specimens: 4 simulated swab/urine samples, 2 mL

Examinations: Direct multiplex nucleic acid detection. Pathogens included are *C. trachomatis,M. genitalium, M. hominis, N. gonorrhoeae, T. vaginalis, U. parvum and U. urealyticum.*

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

EQA schemes for microbiology POCT

Microbiology

5640 EBV mononucleosis, POCT
5635 Dengue virus, antibodies and antigen detection
5860 *Helicobacter pylori*, antibodies
5596 *Helicobacter pylori*, antigen detection in faeces
5090 HIV, antibodies and antigen detection, POCT
5671 Influenza virus A+B, antigen detection
5597 Legionella, antigen detection in urine
5430 Malaria, antigen and nucleic acid detection
5980 *Mycoplasma pneumoniae*, antibodies
5560 Puumala virus, antibodies
5673 Respiratory adenovirus, antigen detection
5098 Rotavirus and adenovirus, antigen detection
5672 RS virus, antigen detection
5677 SARS CoV-2, antibodies
5681 SARS-CoV-2 antigen detection
5676 SARS-CoV-2 nucleic acid detection
5595 *Streptococcus pyogenes*, group A, antigen detection in pharyngeal sample
5599 *Streptococcus agalactiae* (GBS), nucleic acid detection
5598 *Streptococcus pneumoniae*, antigen detection in urine
5099 Tick-borne encephalitis virus, antibodies
5473 *Trichomonas vaginalis*, detection

LABQUALITY

Sales and customer service

Tel. +358 9 8566 8200 | Fax +358 9 8566 8280

info@labquality.fi | www.labquality.com

Kumpulantie 15, FI-00520 Helsinki, Finland

VAT FI01100791